Beatrice Bassetti

Beatrice Bassetti

Auto-generated profile, based on publicly available information

Beatrice Bassetti

Vascular Biology and Regenerative Medicine Unit, Centro Cardiologico Monzino, IRCCS, Milan, Italy

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
YDYuri D'Alessandra
Yuri D'Alessandra
MCMaria Cristina Carena
Maria Cristina Carena
LSLiana Spazzafumo
Liana Spazzafumo
FMFederico Martinelli
Federico Martinelli
BBBeatrice Bassetti
Beatrice Bassetti
Giulio PompilioGiulio Pompilio
Giulio Pompilio
We examined circulating miRNA expression profiles in plasma of patients with coronary artery disease (CAD) vs. matched controls, with the aim of identifying novel discriminating biomarkers of Stable (SA) and Unstable (UA) angina. An exploratory analysis of plasmatic expression profile of 367 miRNAs was conducted in a group of SA and UA patients and control donors, using TaqMan microRNA Arrays. Screening confirmation and expression analysis were performed by qRT-PCR: all miRNAs found dysregulated were examined in the plasma of troponin-negative UA (n=19) and SA (n=34) patients and control subjects (n=20), matched for sex, age, and cardiovascular risk factors. In addition, the expression of 14 known CAD-associated miRNAs was also investigated. Out of 178 miRNAs consistently detected in plasma samples, 3 showed positive modulation by CAD when compared to controls: miR-337-5p, miR-433, and miR-485-3p. Further, miR-1, -122, -126, -133a, -133b, and miR-199a were positively modulated in both UA and SA patients, while miR-337-5p and miR-145 showed a positive modulation only in SA or UA patients, respectively. ROC curve analyses showed a good diagnostic potential (AUC ≥ 0.85) for miR-1, -126, and -483-5p in SA and for miR-1, -126, and -133a in UA patients vs. controls, respectively. No discriminating AUC values were observed comparing SA vs. UA patients. Hierarchical cluster analysis showed that the combination of miR-1, -133a, and -126 in UA and of miR-1, -126, and -485-3p in SA correctly classified patients vs. controls with an efficiency ≥ 87%. No combination of miRNAs was able to reliably discriminate patients with UA from patients with SA. This work showed that specific plasmatic miRNA signatures have the potential to accurately discriminate patients with angiographically documented CAD from matched controls. We failed to identify a plasmatic miRNA expression pattern capable to differentiate SA from UA patients.

1 January 2018 in Pharmacological Research
Verified
Journal Article
Closed access
PNPatrizia Nigro
Patrizia Nigro
BBBeatrice Bassetti
Beatrice Bassetti
LCLaura Cavallotti
Laura Cavallotti
VCValentina Catto
Valentina Catto
CCCorrado Carbucicchio
Corrado Carbucicchio
Giulio PompilioGiulio Pompilio
Giulio Pompilio

15 May 2014 in Diabetes
Verified
Journal Article
Open access
PDF file
MVMatteo Vecellio
Matteo Vecellio
FSFrancesco Spallotta
Francesco Spallotta
SNSimona Nanni
Simona Nanni
CCClaudia. Colussi
Claudia. Colussi
CCChiara Cencioni
Chiara Cencioni
Carlo GaetanoCarlo Gaetano
Carlo Gaetano
This study investigates the diabetes-associated alterations present in cardiac mesenchymal cells (CMSC) obtained from normoglycemic (ND-CMSC) and type 2 diabetic patients (D-CMSC), identifying the histone acetylase (HAT) activator pentadecylidenemalonate 1b (SPV106) as a potential pharmacological intervention to restore cellular function. D-CMSC were characterized by a reduced proliferation rate, diminished phosphorylation at histone H3 serine 10 (H3S10P), decreased differentiation potential, and premature cellular senescence. A global histone code profiling of D-CMSC revealed that acetylation on histone H3 lysine 9 (H3K9Ac) and lysine 14 (H3K14Ac) was decreased, whereas the trimethylation of H3K9Ac and lysine 27 significantly increased. These observations were paralleled by a downregulation of the GCN5-related N-acetyltransferases (GNAT) p300/CBP-associated factor and its isoform 5-α general control of amino acid synthesis (GCN5a), determining a relative decrease in total HAT activity. DNA CpG island hypermethylation was detected at promoters of genes involved in cell growth control and genomic stability. Remarkably, treatment with the GNAT proactivator SPV106 restored normal levels of H3K9Ac and H3K14Ac, reduced DNA CpG hypermethylation, and recovered D-CMSC proliferation and differentiation. These results suggest that epigenetic interventions may reverse alterations in human CMSC obtained from diabetic patients.

1 September 2015 in Cytotherapy
Verified
Journal Article
Open access
GSGabriella Spaltro
Gabriella Spaltro
SSStefania Straino
Stefania Straino
EGElisa Gambini
Elisa Gambini
BBBeatrice Bassetti
Beatrice Bassetti
LPLuca Persico
Luca Persico
Giulio PompilioGiulio Pompilio
Giulio Pompilio
The Pall Celeris system is a filtration-based point-of-care device designed to obtain a high concentrate of peripheral blood total nucleated cells (PB-TNCs). We have characterized the Pall Celeris-derived TNCs for their in vitro and in vivo angiogenic potency. PB-TNCs isolated from healthy donors were characterized through the use of flow cytometry and functional assays, aiming to assess migratory capacity, ability to form capillary-like structures, endothelial trans-differentiation and paracrine factor secretion. In a hind limb ischemia mouse model, we evaluated perfusion immediately and 7 days after surgery, along with capillary, arteriole and regenerative fiber density and local bio-distribution. Human PB-TNCs isolated by use of the Pall Celeris filtration system were shown to secrete a panel of angiogenic factors and migrate in response to vascular endothelial growth factor and stromal-derived factor-1 stimuli. Moreover, after injection in a mouse model of hind limb ischemia, PB-TNCs induced neovascularization by increasing capillary, arteriole and regenerative fiber numbers, with human cells detected in murine tissue up to 7 days after ischemia. The Pall Celeris system may represent a novel, effective and reliable point-of-care device to obtain a PB-derived cell product with adequate potency for therapeutic angiogenesis.

11 July 2014 in Stem Cells and Development
Verified
Journal Article
Closed access
DBDario Bongiovanni
Dario Bongiovanni
BBBeatrice Bassetti
Beatrice Bassetti
EGElisa Gambini
Elisa Gambini
GGGiuseppe Gaipa
Giuseppe Gaipa
Giacomo FratiGiacomo Frati
Giacomo Frati
Giulio PompilioGiulio Pompilio
Giulio Pompilio
Ischemic diseases are the major cause of death and morbidity in Western countries. In the last decade, cell therapy has been suggested to be a promising treatment both in acute/chronic myocardial and peripheral ischemia. Different cell lineages have been tested, including endothelial progenitor cells. A subpopulation of bone marrow-derived immature ECPs, expressing the highly conserved stem cell glycoprotein antigen prominin-1 or CD133 marker, was shown to possess pro-angiogenic and antiapoptotic effects on ischemic tissues. The mechanisms implicated in CD133 + cells ability to contribute to neovascularization processes have been attributed to their ability to directly differentiate into newly forming vessels and to indirectly activate pro-angiogenic signaling by paracrine mechanisms. A large body of in vivo experimental evidences has demonstrated the potential of CD133 + cells to reverse ischemia. Moreover, several clinical trials have reported promising beneficial effects after infusion of autologous CD133 + into ischemic heart and limbs exploiting various delivery strategies. These trials have contributed to characterize the CD133 + manufacturing process as an advanced cell product (AMP). The aim of this review is to summarize available experimental and clinical data on CD133 + cells in the context of myocardial and peripheral ischemia, and to focus on the development of the CD133 + cell as an anti-ischemic AMP.

1 November 2012 in Translational Research
Verified
Journal Article
Closed access
EGElisa Gambini
Elisa Gambini
Maurizio PesceMaurizio Pesce
Maurizio Pesce
LPLuca Persico
Luca Persico
BBBeatrice Bassetti
Beatrice Bassetti
AGAntonio Gambini
Antonio Gambini
Giulio PompilioGiulio Pompilio
Giulio Pompilio